US2019330342A1PendingUtilityA1
Methods and compositions for inhibiting cd32b expressing cells
Est. expiryMay 30, 2027(~0.8 yrs left)· nominal 20-yr term from priority
A61P 37/08A61P 37/06A61P 35/00A61P 3/10A61P 29/00A61P 1/00A61P 19/02C07K 16/2803C07K 2317/734C07K 2317/72C07K 2317/732C07K 16/2851C07K 2317/31C07K 2317/24C07K 16/2878C07K 16/283C07K 2317/77C07K 2317/53C07K 2317/52C07K 2317/71C07K 2317/524C07K 2317/76C07K 2317/92C07K 2317/73C07K 16/00A61K 2039/505
75
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to immunoglobulins that bind FcγRIIb+ cells and coengage the antigen on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
Claims
exact text as granted — not AI-modified1 - 20 . (canceled)
21 . A method of inducing dendritic cell proliferation in a patient in need thereof comprising:
administering to the patient an effective amount of anti-human CD40 antibody comprising a light chain and a heavy chain, the heavy chain comprising a human IgG1 Fc domain comprising a S267E amino acid substitution, wherein the numbering is according to the EU index as in Kabat, thereby inducing dendritic cell proliferation in the patient.
22 . A method of activating B cells in a patient in need thereof comprising:
administering to the patient an effective amount of anti-human CD40 antibody comprising a light chain and a heavy chain, the heavy chain comprising a human IgG1 Fc domain comprising a S267E amino acid substitution, wherein the numbering is according to the EU index as in Kabat, thereby activating B cells in the patient.Join the waitlist — get patent alerts
Track US2019330342A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.